Log in
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 

MarketScreener Homepage  >  Equities  >  Nyse  >  Pfizer, Inc.    PFE


SummaryMost relevantAll NewsPress ReleasesOfficial PublicationsSector newsMarketScreener StrategiesAnalyst Recommendations

J&J plans to test its COVID-19 vaccine in ages 12-18 soon

10/30/2020 | 12:16pm EST

NEW YORK, Oct 30 (Reuters) - Johnson & Johnson plans to start testing its experimental COVID-19 vaccine in youths aged 12 to 18 as soon as possible, and the company's previous experience with the same technology in a vaccine successfully used in children could give it a leg up with regulators.

"We plan to go into children as soon as we possibly can, but very carefully in terms of safety," J&J's Dr. Jerry Sadoff told a virtual meeting of the U.S. Centers for Disease Control and Prevention's (CDC) Advisory Committee on Immunization Practices on Friday.

Depending on safety and other factors, the company plans to test in even younger children afterwards, said Sadoff, a vaccine research scientist at J&J's Janssen unit, without giving a timeline.

J&J said in a statement that it is currently in discussions with regulators and partners regarding the inclusion of the pediatric population in its trials.

The U.S. Food and Drug Administration has said it is important for drugmakers to test their vaccines in children. Some doctors have raised concerns that the vaccines themselves could trigger a rare, life-threatening condition called Multisystem Inflammatory Syndrome in some children.

Rival drugmaker Pfizer Inc has already begun testing the COVID-19 vaccine it is developing with Germany's BioNTech in children as young as 12. Their vaccine uses messenger RNA (mRNA), a new technology that has yet to produce an approved vaccine. J&J's uses a cold virus to deliver coronavirus genetic material in order to spur an immune response. The platform - called AdVac - is used in a vaccine for Ebola that was approved in Europe earlier this year and used on more than 100,000 people, including infants, children, and pregnant women.

The technology's history of safety should be important to regulators, said Dr. Paul Spearman, director of the infectious diseases division of Cincinnati Children's Hospital.

"Most of the toxicities are going to come from the platform and not from putting a different insert into the platform, Spearman said. So replacing the Ebola genetic material with that of the novel coronavirus "is unlikely to give you major issues," he added.

J&J started testing the vaccine in adults in a 60,000-volunteer Phase III study in late September. It had to pause the trial earlier this month because of a serious medical event in one participant. The study resumed last week. (Reporting by Michael Erman Editing by Chizu Nomiyama and Bill Berkrot)

© Reuters 2020
All news about PFIZER, INC.
05:59pU.S. Panel Recommends Giving First Covid Vaccines to Health Workers, Nursing ..
05:27pGlobal equity markets jump, bonds dip, on hopes of vaccine-led recovery
05:24pPFIZER : Pushed to rush, FDA head says feds will get vaccine 'right'
05:20pBrazil sees one-dose, unfrozen vaccine as ideal for COVID-19 -official
04:43pPFIZER : Key dates as US regulators weigh emergency use of vaccines
04:37pHealth Care Up As Hospital Chains Rebound -- Health Care Roundup
02:51pS&P 500, Nasdaq hit records on vaccine optimism
01:05pUS PANEL : 1st vaccines to health care workers, nursing homes
01:01pTrump to meet COVID-19 vaccine makers, distributors next week - Stat News
12:50pPFIZER : On Pace for Highest Close Since July 2019 -- Data Talk
More news
Financials (USD)
Sales 2020 49 265 M - -
Net income 2020 19 717 M - -
Net Debt 2020 35 033 M - -
P/E ratio 2020 19,6x
Yield 2020 3,81%
Capitalization 219 B 219 B -
EV / Sales 2020 5,16x
EV / Sales 2021 4,59x
Nbr of Employees 88 300
Free-Float 59,1%
Duration : Period :
Pfizer, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends PFIZER, INC.
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 22
Average target price 42,15 $
Last Close Price 39,41 $
Spread / Highest target 39,6%
Spread / Average Target 6,95%
Spread / Lowest Target -11,2%
EPS Revisions
Albert Bourla Chairman, Chief Executive & Operating Officer
Frank A. D'Amelio Chief Financial Officer & EVP-Business Operations
Lidia L. Fonseca Executive VP, Chief Digital & Technology Officer
Wyllie Don Cornwell Independent Director
Suzanne Nora Johnson Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
PFIZER, INC.3.21%212 942
JOHNSON & JOHNSON-0.82%380 876
ROCHE HOLDING AG-4.76%282 467
NOVARTIS AG-10.48%206 479
MERCK & CO., INC.-11.61%203 389
ABBVIE INC.18.12%184 633